磁共振成像与质子磁共振波谱鉴别强化性胶质瘤与恶性淋巴瘤
结果显示ADC最小值有鉴别价值(AUC 0.852),LCModel MRS在Glu、NAA+NAAG、Glu+谷氨酰胺及Lip13a+Lip13b上存在组间差异,其中Glu的AUC最大(0.904)。结论认为LCModel定量质子MRS是鉴别胶质瘤与恶性淋巴瘤的有价值方法。
要点
- ADC最小值有助于鉴别恶性淋巴瘤与胶质瘤,AUC为0.852。
- LCModel MRS显示Glu、NAA+NAAG、Glu+谷氨酰胺及Lip13a+Lip13b存在组间差异。
- Glu的AUC最大(0.904),其次为NAA+NAAG(0.883)和Lip13a+Lip13b(0.866)。
核心结论
- LCModel定量质子MRS被认为是鉴别胶质瘤与恶性淋巴瘤的有价值方法。
研究设计与样本
- 回顾性评估59例病例的临床特征、常规MRI表现及LCModel质子MRS参数,以寻找鉴别恶性淋巴瘤与强化性胶质瘤的因素。
- 病例包括13例恶性淋巴瘤、1例毛细胞型星形细胞瘤、5例Ⅱ级胶质瘤、5例Ⅲ级胶质瘤和35例胶质母细胞瘤。
主要发现
- 性别和年龄等临床特征与诊断无相关性。
- T1加权和T2加权图像均无助于鉴别两类肿瘤,而ADC最小值有鉴别价值,AUC为0.852。
- LCModel MRS分析显示恶性淋巴瘤与胶质瘤之间在Glu、NAA+NAAG、Glu+谷氨酰胺及Lip13a+Lip13b上存在差异。
- Glu的AUC最大,为0.904;NAA+NAAG为0.883,Lip13a+Lip13b为0.866。
临床怎么用
- 对于术前难以鉴别的强化性胶质瘤与恶性淋巴瘤,可结合ADC最小值及LCModel质子MRS定量参数(尤其Glu)辅助判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the treatment strategies for malignant lymphomas and gliomas differ, it is usually difficult to preoperatively distinguish between them. Magnetic resonance spectroscopy (MRS) was recently reported to be useful for preoperative diagnoses; however, MRS data analysis using LCModel, which is a quantitative and objective method, was performed in only a few of the existing reports. METHODS: The clinical characteristics, conventional magnetic resonance imaging findings, and MRS parameters using LCModel were evaluated to identify the factors that can help distinguish between malignant lymphomas and enhanced gliomas. RESULTS: In total, 59 cases were evaluated, including 13 cases of malignant lymphoma, 1 case of pilocytic astrocytoma, 5 cases of grade Ⅱ glioma, 5 cases of grade Ⅲ glioma, and 35 cases of glioblastoma. There was no correlation between clinical characteristics (sex and age) and diagnosis. Neither T1- nor T2-weighted image was useful for differentiation between the 2 forms of tumors, but the apparent diffusion coefficient minimum value was useful for distinguishing malignant lymphomas from gliomas, with an area under the curve (AUC) value of 0.852. MRS analysis using LCModel revealed differences in glutamate (Glu), N-acetylaspartate (NAA) + N-acetylaspartylglutamate (NAAG), Glu + glutamine, and Lipid (Lip) 13a + Lip13b between malignant lymphomas and gliomas. The largest AUC was 0.904, which was obtained for the Glu level, followed by 0.883 and 0.866 for NAA + NAAG and Lip13a + Lip13b, respectively. CONCLUSIONS: Quantitative analysis of proton-MRS using LCModel is considered to be a valuable method for distinguishing between gliomas and malignant lymphomas.
引用
- Ohba S, Murayama K, Abe M, et al. Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy for Differentiating Between Enhanced Gliomas and Malignant Lymphomas. World Neurosurg. 2019. PMID: 30951915. doi:10.1016/j.wneu.2019.03.261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。